PL368565A1 - Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma - Google Patents

Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma

Info

Publication number
PL368565A1
PL368565A1 PL02368565A PL36856502A PL368565A1 PL 368565 A1 PL368565 A1 PL 368565A1 PL 02368565 A PL02368565 A PL 02368565A PL 36856502 A PL36856502 A PL 36856502A PL 368565 A1 PL368565 A1 PL 368565A1
Authority
PL
Poland
Prior art keywords
lasik
trauma
injury
compounds
treating conditions
Prior art date
Application number
PL02368565A
Other languages
English (en)
Polish (pl)
Inventor
Mark R. Hellberg
Lok-Hou Pang
John M. Yanni
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Publication of PL368565A1 publication Critical patent/PL368565A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL02368565A 2001-08-29 2002-07-23 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma PL368565A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31565201P 2001-08-29 2001-08-29

Publications (1)

Publication Number Publication Date
PL368565A1 true PL368565A1 (en) 2005-04-04

Family

ID=23225436

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02368565A PL368565A1 (en) 2001-08-29 2002-07-23 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma

Country Status (10)

Country Link
EP (1) EP1420791A4 (fr)
JP (1) JP2005502678A (fr)
CN (1) CN1549718A (fr)
AR (1) AR036194A1 (fr)
BR (1) BR0212151A (fr)
CA (1) CA2455896A1 (fr)
MX (1) MXPA04001255A (fr)
PL (1) PL368565A1 (fr)
WO (1) WO2003020281A1 (fr)
ZA (1) ZA200400837B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370245T3 (es) * 2003-04-18 2011-12-13 Senju Pharmaceutical Co., Ltd. 2-cloro-6,7-dimetoxi-n-[5-(1)h-indazolil]quinazolina-4-amina, dihidrocloruro de n-(1-bencil-4-piperidinil)-1h-indazol-5-amina, ácido 4-[2-(2,3,4,5,6-pentafluorofenil)acriloil]cinámico e hidrocloruro de fasudilo para uso en la recuperación de la percepción corneal.
ES2234428B1 (es) * 2003-12-09 2006-11-01 Universidad Miguel Hernandez Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva.
WO2005102375A1 (fr) * 2004-04-23 2005-11-03 Senju Pharmaceutical Co., Ltd. Promoteur de la neuritogénèse de la cornée contenant du pacap et son dérivé
KR101213766B1 (ko) 2004-06-03 2012-12-18 미쓰비시 타나베 파마 코퍼레이션 아미드 화합물을 포함하는 각막 민감도의 회복제
EP1859795A4 (fr) * 2005-03-15 2008-06-04 Ono Pharmaceutical Co Agent therapeutique pour les maladies ophtalmiques
CN113350326B (zh) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
WO2001085152A2 (fr) * 2000-05-10 2001-11-15 Alcon, Inc. R-eliprodil applique au traitement du glaucome

Also Published As

Publication number Publication date
WO2003020281A1 (fr) 2003-03-13
EP1420791A4 (fr) 2004-09-15
CA2455896A1 (fr) 2003-03-13
CN1549718A (zh) 2004-11-24
JP2005502678A (ja) 2005-01-27
BR0212151A (pt) 2004-08-24
ZA200400837B (en) 2005-02-02
MXPA04001255A (es) 2004-05-27
AR036194A1 (es) 2004-08-18
EP1420791A1 (fr) 2004-05-26

Similar Documents

Publication Publication Date Title
EP1592435A4 (fr) Formulation ophtalmique pour la prevention et le traitement de pathologies oculaires
WO2006071548A3 (fr) Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase
WO2006066103A3 (fr) Implant ophtalmique pour traitement du glaucome
WO2007076360A8 (fr) (indazol-5-yl)-pyrazines et (1,3-dihydro-indol-2-un)- pyrazines pour le traitement de maladies et de conditions a mediation de rho kinase
GB2402674B (en) Compositions and methods for the treatment of glaucoma or ocular hypertension
IL158775A0 (en) Use of an antioxidant for treating and or preventing surface ocular disorders
DE60045048D1 (de) Skleraprothese zur Behandlung der Weitsichtigkeit und anderer Augenkrankheiten
HUP0401605A3 (en) Integrin inhibitors for the treatment of eye diseases
DE69930271T8 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
AU6391000A (en) Method of preventing the injury or death of retinal cells and treating ocular diseases
WO2000018387A3 (fr) Compositions antibiotiques pour le traitement des yeux, des oreilles et du nez
HU0002963D0 (en) Methods and compositions for treating diseases and conditions of the eye field of invention
WO2002079149A3 (fr) Nouveaux composes de dihydropyrimidine cyano substituee et leur utilisation therateutique
WO2000066139A3 (fr) Procedes biochimiques permettant d'eliminer les taies, les opacifications et le flou de la cornee
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
EP1420791A4 (fr) Utilisation de composes permettant de traiter des affections consecutives a une lesion du nerf corneen apres un lasik ou d'autres traumatismes ou chirurgies de l'oeil
EP1406648A4 (fr) Utilisation d'un derive d'angiotensine i en tant qu'agent therapeutique et preventif pour les lesions et les troubles cardiaques du type infarctus
EP1455780A4 (fr) Nouveaux derives de benzodifurane imidazoline et de benzofurane imidazoline et leur utilisation pour traiter le glaucome
EP1581209A4 (fr) Nouveaux analogues de benzopyranne et leur utilisation pour le traitement du glaucome
CA2414586A1 (fr) Agent de traitement therapeutique des maladies du nerf optique et de maladies semblables
EP1482922A4 (fr) Agents pour une administration corneenne ou intrastromale pour traiter ou empecher les troubles oculaires
ZA200400210B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
WO2005102297A3 (fr) Agents angiostatiques et procedes et compositions de controle de l'hypertension oculaire